Skip to main content

Table 2 Baseline characteristics of patients included in the study

From: Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin

Characteristic

2–3 (n = 22)

4–8 (n = 18)

9–11 (n = 19)

12–14 (n = 22)

Weighta, kg

12.6 (11.5–13.8)

19.4 (16.4–21.8)

33(31–36)

46 (40–52)

Body surface areaa, m2

0.57 (0.54–0.60)

0.79 (0.70–0.8)

1.13 (1.09–1.2)

1.4 (1.29–1.5)

Parasitemia at admission, geometrical mean and standard deviation

4420 (3.64)

3637 (2.68)

1639 (3.39)

3528 (5.92)

Number of patients with parasitemia on day 3,

4

3

nd

nd

Parasitemia on day 3, geometrical mean and range

81.44 (52–320)

15 (10–32)

nd

nd

Parasite clearancea, h

60 (24–96)

48 (24–72)

48 (24–60)

48 (24–60)

Previous episodes of malaria, %

60

80

90

90

History of fever in the least 48 h, %

92

85

90

80

Time for fever clearancea, h

24 (12–48)

24 (12–60)

24 (12–60)

24 (12–60)

Hemoglobina, g/dl

11.8 (10.9–12.5)

12.1 (11–13.5)

12.6 (11.1–12.8)

13.4 (12.1–14.5)

Hematocrita, %

34 (29–37)

36 (29–38)

36 (29–39)

38 (31–40)

Plateletsa, mm3

212,000 (190,000–280,000)

235,000 (160,000–270,000)

242,000 (185,000–310,000)

260,000 (195,000–320,000)

  1. Nd not determined
  2. aValues are expressed as median and range